These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30117318)

  • 21. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).
    Han SY; Mrózek K; Voutsinas J; Wu Q; Morgan EA; Vestergaard H; Ohgami R; Kluin PM; Kristensen TK; Pullarkat S; Møller MB; Schiefer AI; Baughn LB; Kim Y; Czuchlewski D; Hilberink JR; Horny HP; George TI; Dolan M; Ku NK; Arana Yi C; Pullarkat V; Kohlschmidt J; Salhotra A; Soma L; Bloomfield CD; Chen D; Sperr WR; Marcucci G; Cho C; Akin C; Gotlib J; Broesby-Olsen S; Larson M; Linden MA; Deeg HJ; Hoermann G; Perales MA; Hornick JL; Litzow MR; Nakamura R; Weisdorf D; Borthakur G; Huls G; Valent P; Ustun C; Yeung CCS
    Blood Adv; 2021 May; 5(10):2481-2489. PubMed ID: 34003250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
    Ustun C; Marcucci G
    Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
    Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.
    Nguyen S; Leblanc T; Fenaux P; Witz F; Blaise D; Pigneux A; Thomas X; Rigal-Huguet F; Lioure B; Auvrignon A; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Socié G; Dombret H
    Blood; 2002 May; 99(10):3517-23. PubMed ID: 11986202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Chen W; Xie H; Wang H; Chen L; Sun Y; Chen Z; Li Q
    PLoS One; 2016; 11(1):e0146614. PubMed ID: 26771376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22).
    Wen L; Xia J; Wang Q; Yao H; Xie J; Pan J; Xue Y; Wu D; Chen S
    Int J Hematol; 2015 Aug; 102(2):205-10. PubMed ID: 26040504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
    Solh M; Yohe S; Weisdorf D; Ustun C
    Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
    Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations.
    Lin P; Chen L; Luthra R; Konoplev SN; Wang X; Medeiros LJ
    Mod Pathol; 2008 Aug; 21(8):1029-36. PubMed ID: 18536654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual color FISH on CBF primary acute myeloid leukemia.
    Sorour A; Nafea D
    Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
    Shafik NF; Ibraheem D; Selim MM; Allam RM; Fathalla LA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e363-e375. PubMed ID: 34972661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
    Marcucci G; Caligiuri MA; Bloomfield CD
    Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
    Marcucci G; Caligiuri MA; Bloomfield CD
    Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
    Schoch C; Haase D; Haferlach T; Gudat H; Büchner T; Freund M; Link H; Lengfelder E; Wandt H; Sauerland MC; Löffler H; Fonatsch C
    Leukemia; 1996 Aug; 10(8):1288-95. PubMed ID: 8709633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
    Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
    Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.